Overview

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Factor VIII